BrainSight AI, a neuroscience-focused startup, has raised $5 million in a pre-Series A funding round. The investment was led by IAN Alpha Fund, with participation from IvyCap Ventures, Silver Needle, and existing investors. This Bengaluru-based company had earlier received $925,000 from Pfizer and other backers.
The new funds will be used to expand BrainSight AI’s reach to Tier I and Tier II cities in India. The company also plans to venture into Africa and Southeast Asia while entering the U.S. market by securing FDA certification. A portion of the funds will go towards research and development to create new solutions for patients and caregivers.
What Does BrainSight AI Do?
BrainSight AI was founded in 2019 by Laina Emmanuel, an ISB graduate, and Rimjhim Agrawal, a NIMHANS PhD. The company uses artificial intelligence (AI) and neuroscience to improve the diagnosis and treatment of brain disorders.
BrainSight AI’s flagship products include:
- Voxelbox: An advanced fMRI processing tool powered by machine learning to deliver detailed brain imaging.
- Snowdrop: A patient-care app designed to help patients follow treatment plans effectively.
Collaborations with Hospitals
BrainSight AI currently partners with over 40 hospitals across India, providing support in neurosurgery and radiology. The company’s tools are especially valuable for planning surgeries involving brain tumors.
By mapping the brain’s neural connections, BrainSight AI’s technology helps doctors perform safer and more precise surgeries. It also enables the treatment of a wide range of neurological and psychiatric conditions.
Global Vision for Brain Care
BrainSight AI aims to make advanced brain care accessible to hospitals worldwide, breaking barriers that previously restricted such technology to elite institutions like Harvard and Stanford. The company plans to triple its current user base and promote awareness of connectomics, a field that studies brain networks to personalize medical care.
Co-founder and CEO Laina Emmanuel believes this approach is transformative, as it allows doctors to identify critical brain functions before surgery. The company is also working on caregiver-focused apps and expanding its R&D efforts to enhance neuro-oncological and neuropsychiatric diagnoses.
With its new funding, BrainSight AI is poised to shape the future of neuroscience by democratizing advanced brain care. By expanding its operations globally and driving innovation, the startup hopes to improve the lives of patients and caregivers worldwide.
